ERBB2 and breast cancer: Unlike luminal patients, both HER2‐enriched patients (SHR, 1.77; 95% CI, 1.17–2.69; p = 0.007) and TNBC patients (SHR, 2.06; 95% CI, 1.64–2.58; p < 0.001) were found to have a higher risk of dying from BC.